Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gallagher

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
The British Journal of Radiology|April 18, 2025
MRI-based radiomics nomogram to predict complete response to definitive chemoradiation in patients with anal cancerHugo C Temperley, Fariba Tohidinezhad, Niall J O'Sullivan, et al.
The Oncologist|April 5, 2022
The Essentials of MultiomicsJohn L Marshall, Beth N Peshkin, Takayuki Yoshino, et al.
Journal of Cheminformatics|September 3, 2010
Collaborative development of predictive toxicology applicationsBarry Hardy, Nicki Douglas, Christoph Helma, et al.
Breast Cancer Research : BCR|May 21, 2025
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACENasim Mavaddat, Debra Frost, Emily Zhao, et al.
Familial Cancer|January 17, 2017
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controlsSibel Saya, Emma Killick, Sarah Thomas, et al.
Journal of Medical Genetics|November 14, 2019
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic <i>TP53</i> mutation carriers: a case-controlled study (SIGNIFY)Elizabeth K Bancroft, Sibel Saya, Emma Brown, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
British Journal of Cancer|January 5, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
British Journal of Cancer|March 7, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
The British Journal of Radiology|April 18, 2025
MRI-based radiomics nomogram to predict complete response to definitive chemoradiation in patients with anal cancerHugo C Temperley, Fariba Tohidinezhad, Niall J O'Sullivan, et al.
The Oncologist|April 5, 2022
The Essentials of MultiomicsJohn L Marshall, Beth N Peshkin, Takayuki Yoshino, et al.
Journal of Cheminformatics|September 3, 2010
Collaborative development of predictive toxicology applicationsBarry Hardy, Nicki Douglas, Christoph Helma, et al.
Breast Cancer Research : BCR|May 21, 2025
Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACENasim Mavaddat, Debra Frost, Emily Zhao, et al.
Familial Cancer|January 17, 2017
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controlsSibel Saya, Emma Killick, Sarah Thomas, et al.
Journal of Medical Genetics|November 14, 2019
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic <i>TP53</i> mutation carriers: a case-controlled study (SIGNIFY)Elizabeth K Bancroft, Sibel Saya, Emma Brown, et al.
European Urology|February 4, 2014
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft, Elizabeth C Page, Elena Castro, et al.
British Journal of Cancer|January 5, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
British Journal of Cancer|March 7, 2018
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predispositionChristos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Pageof 7